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Abstract 
Hereditary transthyretin amyloidosis (ATTRv, v for variant) is a late-onset, autosomal dominant disease caused by 
progressive extracellular deposition of transthyretin amyloid fibrils, leading to organ damage and death. For other 
late-onset fatal diseases, as Huntington’s disease, protocols for pre-symptomatic genetic testing (PST) are available 
since decades. For ATTRv, limited experience has been reported to date, mostly gathered before the availability of 
approved therapies. We aimed at developing recommendations for a safe and feasible PST protocol in ATTRv in the 
era of emerging treatments, taking also into account Italian patients’ characteristics and healthcare system rules. After 
an initial survey on ongoing approaches to PST for ATTRv in Italy, two roundtable meetings were attended by 24 
experts from 16 Italian centers involved in the diagnosis and care of this disease. Minimal requirements for PST offer 
and potential critical issues were highlighted. By November 2019, 457 families affected by ATTRv with 209 molecularly 
confirmed pre-symptomatic carriers were counted. The median age at PST was 41.3 years of age, regardless of the 
specific mutation. Half of the Italian centers had a multidisciplinary team, including a neurologist, an internist, a car-
diologist, a medical geneticist and a psychologist, although in most cases not all the specialists were available in the 
same center. A variable number of visits was performed at each site. Experts agreed that PST should be offered only 
in the context of genetic counselling to at risk individuals aged 18 or older. Advertised commercial options for DNA 
testing should be avoided. The protocol should consist of several steps, including a preliminary clinical examination, 
a pre-test information session, an interval time, the genetic test and a post-test session with the disclosure of the test 
results, in the context of an experienced multidisciplinary team. Recommendations for best timing were also defined. 
Protocols for PST in the context of ATTRv can be refined to offer at risk individuals the best chance for early diagnosis 
and timely treatment start, while respecting autonomous decisions and promoting safe psychological adjustment to 
the genetic result.
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Background
Hereditary transthyretin amyloidosis (ATTRv) is an 
autosomal dominant, late-onset disease caused by the 
extracellular deposition of amyloid fibrils formed by 
misfolded transthyretin mutants [1, 2]. If untreated, the 
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disease is fatal within 4–15 years from onset, according 
to genotype.
More than 130 different mutations of TTR have been 
identified worldwide [3]. The first-described Val30Met 
mutation [4] is the most frequent and may be associ-
ated with an early-onset phenotype, which is common 
in Portuguese population [5], or with a late-onset disease 
which has been described worldwide, including Italy [2, 
6]. Moreover, few Italian regions (Sicily, Puglia, Lazio, 
Piedmont, Tuscan-Emilian Apennines) are endemic for 
specific mutations with variable age at onset and clinical 
presentation [7–10], mostly consisting of a mixed car-
diologic and neurological phenotype. In most cases, the 
clinical onset is around the sixth decade of life [7–10].
For other late-onset neurodegenerative diseases, such 
as Huntington’s disease, familial frontotemporal demen-
tia/amyotrophic lateral sclerosis and spinocerebellar 
ataxias, protocols for pre-symptomatic genetic testing 
(PST) are available since many years [11–14]. These 
counselling protocols govern the access to pre-symp-
tomatic testing in order to protect participants against 
an unfavorable result, providing them with information 
about the disease and the psychosocial consequences of 
the test result. All these protocols aim to conjugate the 
respect for the autonomy with the maximum benefit, 
supporting the applicant in the decision making process 
of testing and helping her/him to cope with the results.
Based on this know-how and on their personal experi-
ence, a few years ago, experts of the European Network 
for TTR-FAP (familial amyloid polyneuropathy) pro-
posed recommendations for pre-symptomatic genetic 
testing and managements of individuals at risk for 
ATTRv [15].
Even if most of those recommendations are still valid, 
during last years the ATTRv therapeutic scenario has 
rapidly changed with an increasing availability of drugs 
that target key molecular events of the amyloidogenesis 
process and are able to treat the disease [2]. Since all 
therapies are maximally effective in the early stages, the 
need to preserve at risk individuals from the psychologi-
cal consequences of a positive test should be balanced 
against the possibility to offer them a close monitoring 
[16], prompting treatment start as soon as minor, but 
clinically meaningful disease signs, are detected.
However, it is difficult to predict treatment onset in 
mutation carriers and to define the optimal timing for 
pre-symptomatic testing. Genetic anticipation has been 
reported in early-onset Val30Met and significant variabil-
ity in age of onset is observed also within families with 
non-Val30Met variants.
Recently, in order to determine when pre-symptomatic 
carriers of a TTR mutation should start a regular moni-
toring, it has been proposed to estimate the predicted age 
of onset of symptomatic disease (PADO). PADO depends 
on the specific TTR gene mutation, the typical age of 
onset for that mutation and the age of onset in other 
members of the proband’s family. International expert 
consensus recommends that regular clinical monitoring 
should start 10 years before the PADO [16].
To promote equal, safe and effective access to PST for 
ATTRv in Italy, experts in the field gathered together to 
agree on best practices and optimal approach. In this 
paper, we address the medical, psychological, ethical, and 
legal issues related to PST for ATTRv and provide recom-
mendations for optimal timing and setting to offer it.
Methods
A preliminary questionnaire (available on request) was 
sent to all participants to evaluate the number of patients 
followed by each center, the number of at risk relatives 
identified, the number of pre-symptomatic carrier that 
developed ATTRv during follow-up monitoring, and the 
protocols locally in use for PST. Available literature on 
genetic counselling in ATTRv was also revised based on 
a PubMed search. We used the following search terms: 
“ATTR amyloidosis” together with “genetic counselling”; 
“pre-symptomatic”; “genetic tests” and “early diagnosis”.
In March and November 2019, two panel discussion 
meetings were attended by 24 ATTRv Italian experts to 
share experiences on PST practices, to identify the main 
controversial issues and to achieve a consensus on best 
PST procedures according to the Italian patients’ popula-
tion and healthcare system characteristics. These experts 
cover all Italian regions and include amyloid-specialized 
centers, genetics units as well as regional centers for rare 
neurological and cardiac diseases. In between and after 
the roundtables, experts circulated comments and con-
tributions to achieve a shared draft. Finally, the consen-
sus document, written by the scientific organizers on the 
basis of all individual inputs was sent to each expert for 
approval.
Questionnaire results
By March 2019, the national Italian reference center in 
Pavia and the other 11 Italian centers followed 457 fami-
lies affected by ATTRv. TTR mutations identified in the 
Italian population are very heterogeneous and include 
(according to historical nomenclature) Val30Met (112; 
25%), Ile68Leu (104; 23%), Phe64Leu (68; 15%), Glu89Gln 
(56; 12%), Val122Ile (11; 2.5%), Tyr78Phe (2; 1%) and 
other variants in the remaining 21.5%. Pre-symptomatic 
carriers were 209, in most cases they had a parent (74%) 
and/or a sibling (33%) affected by ATTRv. PST was per-
formed at a median age of 41 years and 4 months (range 
30–57 years). In all centers the minimum age for testing 
was 18 years. During regular monitoring visits following 
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PST, 26 pre-symptomatic carriers developed clinical 
manifestations of ATTRv amyloidosis. Mean latency 
between detection of the mutation and the onset of the 
disease was 51,08 months (median 51; standard deviation 
38,52; range 6–144).
Half of the Italian centers had a multidisciplinary team 
in place but, in most cases, not all specialists were avail-
able at the same center. For instance, the geneticist was 
present in 7 centers, the psychologist in 6 centers, the 
cardiologist in 5 and an internist in 3 centers. In general, 
lack of a multidisciplinary team or of a particular special-
ist in a team, was due to the lack of resources, particu-
larly in smaller centers, rather than the result of a specific 
choice. The structure of genetic counselling, i.e. the num-
ber of clinical evaluations including a pre-test visit, the 
test-visit and the delivery of the results, was variable 
within the centers according to different experiences and 
to the resources available.
All centers schedule annual follow-up visits for ATTRv 
carriers. These evaluations include neurological and car-
diologic evaluations and usually begin approximately ten 
years before the PADO, in agreement with recent recom-
mendations [16].
Ascertainment and basal clinical evaluation of at‑risk 
subjects
When specialists diagnose a patient with ATTRv, they 
should also communicate that it is important to timely 
inform family members about the risk of disease recur-
rence. All relatives (siblings and offspring) should be 
considered as possible carriers of the mutated allele. 
ATTRv amyloidosis is a progressive and eventually fatal 
disease but treatment options are rapidly expanding and 
changing the natural history of the disease. Thus, the 
patient should be properly educated on the importance 
of informing at risk relatives about the disease, directing 
them to expert clinicians in ATTRv amyloidosis. Indeed, 
the patient and the relatives at risk must be aware that 
the earlier the treatment starts the better it is, as with 
current therapy it is difficult to substantially revert an 
already established damage.
The potential benefits of genetic testing are greater for 
siblings of an index patient than for the offspring. In fact, 
siblings of the index patients, especially those that are 
close to the predicted age of disease onset, are at higher 
risk for developing clinical disease in the immediate 
future and deserve the highest priority.
Occasionally genetic test performed in a sibling may 
reveal an ATTR cardiomyopathy instead of a previously 
misdiagnosed hypertensive or hypertrophic cardiomyo-
pathy heart disease.
Adult subjects at risk of being carriers of TTR mutation 
should start monitoring not later than ten years before 
the PADO. Then, follow-up of genetically confirmed car-
riers will initially take place after 6  months, then every 
12–24 months, and after it will become more frequent as 
the PADO approaches, especially for genotypes associ-
ated with more rapid disease progression (i.e. Val30Met, 
Gly47Glu, Ser77Tyr, Glu89Gln) [16].
Therefore, to appropriately deal with a PST request and 
to avoid possible diagnostic delays, it is relevant to first 
define whether a sibling is already symptomatic or not. A 
specific neurological and/or cardiologic evaluation can be 
offered also considering the phenotype of the mutation 
[2, 6]. Moreover, the clinician should explain overall fea-
tures of ATTRv amyloidosis, the importance to undergo 
genetic analysis as well the significance of genetic results 
[6]. The following evaluations should be performed:
• Neurological evaluation: the at risk individual should 
be asked for possible diagnoses or clinical manifesta-
tions of carpal tunnel syndrome (CTS) [17] and lum-
bar spinal stenosis [18]. Symptoms and signs suggest-
ing neuro-vegetative impairment should be recorded, 
such as pupillary abnormalities, dry eyes or dry 
mouth, abnormal sweating function, vasomotor signs 
(excessively cold hands and cold feet with discol-
oration), orthostatic intolerance (light-headedness, 
dizziness), gastrointestinal signs (nausea, vomiting, 
bloating, early satiety, abdominal colic, incontinence, 
or alternating diarrhea and obstinate constipation), 
genitourinary signs (urinary frequency and urgency, 
incontinence, or increased residual urinary reten-
tion), and sexual dysfunction (difficulty with erection 
and ejaculation) [19].
 Neurological examination should include mental 
state, cranial nerves assessments, examination of 
global and segmental strength, tone and bulk, sen-
sory evaluation and deep tendon reflexes. Gait and 
balance should be also examined. Blood pressure 
should be measured in lying and standing position to 
detect orthostatic hypotension.
• Cardiologic evaluation: in ATTRv, symptomatic car-
diac involvement is mainly characterized by heart 
failure (HF) with preserved ejection fraction [20]. 
The at risk individual should therefore be asked about 
symptoms and signs suggestive of HF, such as: dysp-
nea, fatigue, ankle swelling, dizziness [21]. Neverthe-
less, cardiac amyloidosis may result in a vast range 
of other manifestations, in particular atrial arrhyth-
mias. It is therefore of primary importance that the 
evaluation of the at risk individual is performed by 
a cardiologist with expertise in ATTRv. A 12-lead 
ECG, a comprehensive echocardiographic evaluation 
according to the American Society of Echocardiogra-
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phy recommendations [22] and cardiac biomarkers 
measurements (natriuretic peptides and troponins) 
are the mainstay of cardiologic assessment and 
should always be performed. Such an evaluation rep-
resents the minimum core to be done in at risk sib-
lings of an ATTRv subject.
After clinical and instrumental evaluations, the subject 
at risk is therefore defined as clinically affected or asymp-
tomatic. If clinically affected, a diagnostic genetic test is 
firmly proposed. If it is asymptomatic, he/she can decide 
whether to access the protocol for PST.
PST protocol: minimal steps and requirements
Information and consent
In the absence of an effective preventive therapy, indi-
viduals who undergo pre-test counselling should be 
≥ 18 years old [23].
All people who may wish to take the test should be 
given updated and relevant information in order to make 
an informed voluntary decision. Pre-test counselling 
should include information not only on the test, but also 
about all the testing process.
Extreme care should be used when testing might pro-
vide information about a person, who has not requested 
the test (e.g. 25% at risk) [24]. Pre-symptomatic genetic 
testing is remarkable in that it is one of the few tests 
that can reveal important information about a third part 
who may not wish to have such information. This aspect 
should be drawn to the attention of the participant and 
discussed [11].
Informed consent for the test should be documented 
with the signature of the person to be tested and the pro-
fessional responsible for the counselling as a standard 
medical practice.
The decision to take the test is the unique choice of the 
person concerned. No requests from third parts, be their 
family or otherwise, should be considered.
Laboratory and team requirements
Laboratories which perform genetic testing are expected 
to work under a quality assurance framework, meet rig-
orous standards of accuracy and participate in external 
quality assessment (EQA) schemes.
Nowadays there is increasing concern about the grow-
ing availability of commercial gene panels for human dis-
ease. It is fundamental to underline the need to follow 
established guidelines when performing genetic analysis. 
The entire process should involve teams with expertise in 
providing accurate interpretation of genetic data, patient 
counselling, and disease-specific management and fol-
low up. This kind of support is not available in a com-
mercial “genetic panel” that should therefore be avoided 
[25]. Consequently, PST for ATTRv must be proposed 
only within a solid framework of clinicians who guaran-
tee multidisciplinary management, including the possible 
psychological impact of the test. Therefore, in addition to 
the referral clinician, a psychologist with experience in 
genetic counselling must be available from each team.
Test timing
Excluding exceptional circumstances, a minimum inter-
val (e.g. one month) between the pre-test counselling 
session and the decision whether to take the test is rec-
ommended. Such an interval is necessary to give the per-
son enough time to assimilate the pre-test information 
in order to make an informed and autonomous decision. 
The counsellor should ascertain that the pre-test infor-
mation has been properly understood.
The patient should be aware of the waiting time for 
test, with a clear indication of the time between the sam-
ple being taken and disclosure of results. The entire pro-
cess from pre-test counselling to disclosure of the results 
should not be longer than six months, unless the patient 
himself ask for more time [26].
The result of the predictive test should be delivered as 
soon as reasonably possible after completion of the test 
(preferably within one month from sample collection), 
on a date agreed upon in advance between the center, the 
counsellor, and the person. However, the person should 
have the option to ask for more time delay before receiv-
ing the results or also decide not to receive the results at 
all [23].
Disclosure and confidentiality of the results
The results of the test should be given personally by the 
counsellor to the person who requested the test. As a 
rule, members of the counselling team or the techni-
cal staff should not communicate any information con-
cerning the test and its results to third parts without the 
explicit permission of the person tested (law 2019/2017).
If the genetic analysis is negative for mutation, cli-
nicians must reiterate that the subject is healthy and 
accordingly she/he cannot transmit the disease to her/his 
offspring.
If the genetic analysis is positive, the clinicians must 
communicate and discuss the genetic result. At this 
stage, the need for psychological support should never be 
neglected.
Follow‑up
During PST protocol and post-test contacts specific 
information on follow-up options should be pro-
vided, including (if applicable) participation in clinical 
research studies. The nature of emerging prodromal 
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signs in mutation carriers and their management pos-
sibilities (if available) must be discussed.
If an adult asymptomatic at risk individual resulted 
positive at genetic test, we recommend a systematic fol-
low-up which includes baseline visit and then, if symp-
toms suggestive of disease are not reported, we perform 
a first visit after 6 months and then, if patient is clini-
cally unchanged, every 12–24 months, up to ten years 
before PADO. Then a regular visit every 6–12  months 
is requested.
At each visit, carriers should undergo blood tests 
including a full blood count, hemoglobin, renal func-
tion, albumin, troponin and NT-proBNP, and urine 
examination [15, 27]. Body weight should be measured 
at each examination, and BMI and mBMI calculated 
and monitored. For early detection of the neuropathy 
onset, a full neurologic evaluation is recommended. 
Clinical scales such as NIS (neuropathy impairment 
score), CADT (compound autonomic dysfunction 
test), Kumamoto scale, are useful tools for detecting 
early symptoms and signs. Nerve conduction studies to 
explore large fibers’ function and different tools to eval-
uate small nerve fibers may be employed. Autonomic 
function tests (such as tilt test, deep breathing, sweat 
tests), quantitative sensory tests, laser-evoked poten-
tials, sympathetic skin responses or Electrochemical 
Skin Conductance (ESC) and skin biopsy are all effec-
tive tools for the early detection of small fiber neu-
ropathy [16, 28, 29]. Cardiac evaluation should include 
ECG, 24-h Holter monitoring and echocardiographic 
study. In the case of otherwise unexplained abnormali-
ties in the ECG, echocardiogram study and/or bio-
markers, even in the absence of symptoms suggestive 
of cardiac ATTRv, it should be recommended to reach 
a definitive diagnosis [15, 16]. Scintigraphy with bone 
tracers 99mTc-labeled 3,3-diphosphono-1,2 (DPD) 
propanodicarboxylic acid, 99mTc-labeled pyrophos-
phate (PYP) or 99mTc-labeled pyrophosphate (PYP) 
[30, 31] but not 99mTc-labeled methylene diphospho-
nate (99mTc-MDP]MPD) [32, 33] allows diagnosis of 
transthyretin-related cardiac amyloidosis, in many 
cases even without the need of biopsy [31]. However, it 
is necessary to report the low sensitivity of bone scin-
tigraphy in some TTR mutations such as Phe64Leu in 
which, even in the presence of clear clinical, biochemi-
cal and echocardiographic signs of cardiac involve-
ment, cardiac uptake can be absent [34]. In these cases, 
the use of cardiac magnetic resonance may represent a 
valid alternative [35]. Notably, bone scintigraphy may 
identify amyloid deposition before the development 
of abnormalities on echocardiography [36]. However, 
performing bone scintigraphy without other sugges-
tive symptoms or signs of ATTRv is not recommended, 
since it is not included in the guidelines for the diagno-
sis of ATTRv and this is not routinely carried out in our 
centers.
Finally, a full ophthalmologic examination should be 
performed for the early detection of eye involvement (vit-
reous opacities, glaucoma) [37] and other specialists (i.e. 
gastroenterologist or nephrologist) consultation may be 
required if specific symptoms are reported by the carriers 
[2, 6].
Final remarks
• A referral physician who will take care of the pre-
symptomatic carrier management should be identi-
fied in any referral center. The referral professional 
should discuss and provide the pre-symptomatic car-
rier with a roadmap of management and follow-up 
targeted to the detection of early symptoms and/or 
signs that indicate the initial clinical manifestation of 
ATTR amyloidosis, so to start early a proper therapy.
 Although the results of genetic tests should be bet-
ter discussed in a team context, this is unfeasible in 
the majority of settings. Therefore, depending on the 
center, the referral physician may be a neurologist, 
a cardiologist, a medical geneticist, as long as she/
he has an expertise in genetics, clinical features and 
management of ATTRv.
• A multidisciplinary collaboration is always war-
ranted, with a defined path of care. According to 
expert consensus the key clinical parameters should 
be established at the baseline, then the timing and 
frequency of the clinical and laboratory follow-up 
should be tailored according to symptoms and signs 
associated with any specific mutation. The follow-up 
of pre-symptomatic carrier should include a mul-
tidisciplinary assessment comprehensive of neuro-
logical, cardiologic, ophthalmologist, gastrointestinal 
and, on demand, also nephrological evaluation.
• Pre-symptomatic carriers of TTR mutation should 
start regular monitoring about ten years before 
PADO. Pre-symptomatic carriers should also be 
instructed on the symptoms of the disease, to be 
alerted and ready to contact the treating physician 
also outside of the scheduled visits, if needed. Early 
recognition of symptoms/signs of neuropathy (large 
and small fibers) is crucial since the indication to 
start a specific treatment (both with stabilizers or 
new generation therapies) is almost entirely depend-
ent on the demonstration of the neuropathy.
• Newly identified pre-symptomatic carriers should be 
taken in charge and followed up regularly after the 
return of the diagnostic test, both to monitor their 
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reaction to the communication of the diagnosis, and 
to detect the first signs and symptoms of the disease, 
thus allowing timely therapy starting.
• If, in one of the test steps or subsequently the need 
for specific psychological support is identified, access 
to a psychologist with specific expertise in PST must 
be guaranteed. It is important to allow it also to the 
subjects for whom the mutation has been excluded 
with at least one follow up visit as they might develop 
a negative reaction (survivor guilt) [38].
All final remarks are summarized, as brief practical rec-
ommendations, in Table 1.
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Italy. 12 Department of Neurosciences, Biomedicine and Movement Sciences, 
Section of Neurology, University of Verona and University Hospital GB Rossi, 
Verona, Italy. 13 Unit of Rare Neurodegenerative and Neurometabolic Diseases, 
Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico 
Carlo Besta, Milan, Italy. 14 Neuromuscular Omnicentre (NEMO)-Fondazione 
Serena Onlus, Arenzano, GE, Italy. 15 Department of Neuroscience, Reproduc-
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rara, Italy. 18 Department of Neurosciences, University of Turin, Torino, Italy. 
Table 1 Practical recommendations
Identification of only one clinical referent in each center
Necessity of comprehensive multidisciplinary assessment
Regular monitoring of pre-symptomatic ten years before PADO
Taking in charge newly identified pre-symptomatic carriers
Specific psychological support after pre-symptomatic testing in selected cases
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